SECTOR
Pfizer enters into marketing, distribution agreement with Cipla for 4 brands in India
Dec-19-2025

Pfizer and Cipla have entered into an exclusive marketing and distribution agreement where Cipla will exclusively market and distribute four brands of the company in India. The agreement aims to make the company’s medicines widely available across India by combining its well-established portfolio with Cipla’s deep market reach.

Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India. The company will continue to manufacture, source and supply these medicines to Cipla for India.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

  RELATED NEWS >>